Inflammatory bowel diseases lead to progressive bowel damage and need for surgery. While the increase in prevalence of other immune-mediated diseases in IBD is well recognised, the impact of this on the natural history of IBD is unknown.
SUMMARY Background
Inflammatory bowel diseases lead to progressive bowel damage and need for surgery. While the increase in prevalence of other immune-mediated diseases in IBD is well recognised, the impact of this on the natural history of IBD is unknown.
Aim
To determine the impact of concomitant immune-mediated diseases on phenotypes and outcomes in IBD.
Methods
Patients with IBD enrolled in a prospective registry were queried about the presence of other immune-mediated diseases, defined as those where immune dysregulation plays a role in pathogenesis. Demographics and disease-related information were obtained. Subjects also completed measures of quality of life. Multivariable regression models compared disease phenotype and outcomes of IBD patients with and without other immune-mediated diseases.
INTRODUCTION
Immune-mediated diseases affect up to 10% of the Western population. [1] [2] [3] Among these are inflammatory bowel diseases (IBD) comprising of Crohn's disease (CD) and ulcerative colitis (UC) which are complex chronic immunologically mediated diseases affecting the gastrointestinal tract. [4] [5] [6] Characterised by a protracted course frequently leading to hospitalisations and surgery, they are a source of significant morbidity and impairment of healthrelated quality of life for the affected individuals. [4] [5] [6] [7] [8] Through advances in sequencing technology, over 200 distinct single nucleotide polymorphisms (SNP) contributing to an elevated or reduced risk of IBD have been identified with many shared between CD and UC. 9 Emerging literature suggests that a greater overall burden of these genetic risk alleles may favour earlier onset of disease in CD and predict disease sub-phenotypes, particularly ileal involvement. 10, 11 As well, several environmental factors have been identified that influence both risk of developing disease as well as subsequent course. 12 Despite this, prediction of natural history of disease and occurrence of complications remains challenging. It is well recognised that there is an increased risk for individuals with one immune-mediated disease to develop other immune-mediated diseases. 3, 13, 14 For example, in a prospective study 17% of patients with IBD compared to 10% of patients without IBD had at least one other immune-mediated disease. 14 Such overlap may be due to the known clustering of susceptibility loci between the different immune-mediated diseases and shared pathogenic pathways (such as the IL-12/23 pathway in both CD and psoriasis). 9, 15, 16 The overlap may also be due to common environmental risk factors such as smoking that is known to modulate risk for several immune-mediated diseases including CD, rheumatoid arthritis, and psoriasis. While many studies have investigated the prevalence of concomitant immune-mediated diseases in IBD, few have looked at the impact this has on disease course and it is not known whether affected individuals who have multiple immune-mediated diseases have a more aggressive course of these diseases by virtue of a greater genetic burden. 13, 14, [17] [18] [19] [20] Most of the data investigating this topic has been on the co-existence of primary sclerosing cholangitis and IBD [21] [22] [23] [24] with rare scattered reports on coeliac disease 19 and thyroid disorders. 20 However, investigating this correlation could allow prognostication and selection of therapy for the individual patient by predicting more complicated disease course, and shed light on the phenotypic implications of the shared genetic loci.
Consequently, we performed this study with the following aims: (i) to describe the prevalence of other immune-mediated diseases in a large, well-phenotyped IBD cohort; and (ii) to analyse the effect of co-occurring immune-mediated diseases on the phenotype and outcomes of patients with CD and UC.
METHODS

Study population
Subjects enrolled in the Prospective Registry for IBD Study at Massachusetts General Hospital (PRISM) comprised the study population. Details of this cohort have been previously published. 11, 19 The subjects for this study include all patients with an established diagnosis of CD, UC or IBD-unspecified (IBDU) receiving care at the Massachusetts General Hospital Crohn's and Colitis centre. Upon provision of informed consent, patients completed a detailed questionnaire with a trained research coordinator that included ascertainment of their IBD including age at diagnosis, presence of complications, existence of concomitant diseases, and current and past treatments. All information was confirmed by review of the medical records where available.
Variables
At the time of enrolment, all patients reported other physician-diagnosed immune-mediated diseases which were confirmed via electronic medical record review. Immune-mediated diseases were considered to be one of several organ-specific or systemic diseases, where a dysregulated immune response or immune dysfunction is believed to play a role in its pathogenesis. However, we specifically excluded those that are known extraintestinal manifestations of IBD (such as IBD-related arthritis) and immune-mediated adverse effects of therapy (such as anti-TNF associated psoriasis or lupus). This formed our main covariate of interest and comprised immune-mediated diseases that are not considered extraintestinal manifestations of IBD ( Figure S1 ). Subjects provided information on demographics, age at diagnosis and smoking history. Disease phenotype was classified based on age at diagnosis, location of involvement, and behaviour in patients according to the Montreal classification in CD, and disease extent in UC. 25 30 The primary outcomes for this study included need for anti-TNF biological therapy and for IBD-related surgery.
Statistical analysis
Data were analysed using STATA 13.1 (StataCorp, College Station, Texas, USA). Continuous variables were reported with means and standard deviations and compared using a two sample t-test. Categorical values were expressed as proportions and compared using the chi-square test. Variables found to be significant in the initial univariate analysis at P < 0.05 were analysed using multivariate models. A multivariable logistic regression model was used to calculate the odds ratios (OR) and 95% confidence intervals (CI), investigating the independent association of co-existing immune-mediated diseases with need for biological therapies and surgery, adjusting for potential confounders. For patients where interval between disease diagnosis and time of first resection was available, we used a Cox proportional hazards regression model to estimate hazard ratio (HR) and 95% CI for risk o surgery, stratifying by type of IBD. Survival curves were generated and compared using the log-rank test. A multivariable linear regression model was used to evaluate the regression coefficient and 95% confidence interval for the continuous outcome of quality of life (SF-12 scores and SIBDQ). A two-sided P < 0.05 in the multivariable model indicated independent statistical significance. The Institutional Review Board of Partners Healthcare approved this study.
RESULTS
Study cohort
Of the 2145 patients reviewed, 458 patients (21.4%) had one or more immune-mediated diseases and the remaining 1687 patients (78.6%) had only IBD. The immune-mediated diseases with the highest prevalence were asthma (9.9%), psoriasis (6.1%), and rheumatoid arthritis (2.0%). Disease-specific analysis revealed there was a significant higher prevalence of psoriasis among those with CD compared to UC (8% vs. 4%, P < 0.0001) while the prevalence of PSC (2% vs. 0.5%, P = 0.019) and sarcoidosis (0.4% vs. 0%, P = 0.036) were higher in those with UC compared to CD ( Figure 1 ). There was no significant difference in gender distribution, age at diagnosis, disease duration, or type of IBD between the two groups (Table 1) . Differences in type of immunemediated disease between men and women revealed no differences except for a higher prevalence of Hashimoto's thyroiditis in women compared to men (1.1% vs. 0.3%, P = 0.022) ( Figure 1 ). Specifically among those older than age 50, no differences were noted in the prevalence of any immune-mediated disease between men and women. There was no difference in family history of IBD in people with (33%) or without (32%) another immune-mediated disease (P = 0.66).
In patients with CD, disease extent and behaviour were similar between the group with and without another immune-mediated disease. Specifically, there was no difference in prevalence between isolated colonic CD (22%) compared to those with small bowel disease (23%, P = 0.66). However, in patients with UC, there was a trend towards a larger proportion of those with pancolonic inflammation in those with concomitant immunemediated diseases (62%) compared to those without (52%, P = 0.02). A history of smoking was also more common in patients with concomitant immune-mediated disease (37%) compared to those without (31%, P = 0.02).
Disease outcome and activity associated with concomitant immune-mediated diseases Table 2 presents univariate comparisons of IBD outcomes in patients with concomitant immune-mediated diseases compared to those without. Patients with at least one other immune-mediated disease were significantly more likely to undergo IBD-related surgery (37%) compared to those without (30%, P = 0.04). They were also more likely to have needed anti-TNF biological therapy (53% vs. 45%, P = 0.005) but no different in need for immunomodulators (64% vs. 60%, P = 0.21). Very few patients were on anti-integrin therapy (17 patients (1%) with IBD alone and 3 (0.7%) with an immune-mediated disease, P = 0.49). Cross-sectionally, patients with concomitant immune-mediated diseases were more likely to have elevated HBI (8.1 vs. 3.6, P = 0.04) (but not SCCAI) and higher C-reactive protein (11.2 vs. 8.4, P = 0.02) and ESR (21.0 vs. 17.5, P = 0.01) levels than those without.
Multivariable regression analysis confirmed the increase in use of anti-TNF biologics in patients with another immune-mediated disease (OR 1.31, 95% CI 1.05-1.63) and a modest increase in need for intestinal surgery (OR 1.26, 95% CI 0.99-1.61) without a difference in the need for conventional immunomodulators (OR 1.11, 95% CI 0.89-1.38) ( Table 3) . Subgroup associations by type of IBD (and hence small numbers of patients) demonstrated that the trend towards increased use of biologics remained for both CD and UC, but the differences in need for surgery were no longer statistically significant. There were too few patients with each specific immune-mediated disease to permit robust comparisons. The presence of concomitant PSC was not associated with an increased risk of surgery (OR 0.88, 95% CI 0.29-2.65), immunomodulator (OR 1.31, 95% CI 0.51-3.32) or anti-TNF use (OR 1.15, 95% CI 0.47-2.82).
Time from disease diagnosis to surgery was available for 526 of 676 patients (78%). We performed a Cox hazards regression on risk of surgery in the presence of concomitant immune-mediated disease, stratifying by type of IBD. While there was no increase in risk of surgery among patients with Crohn's disease (HR 1.06, 95% CI 0.86-1.31), there was a significant increased risk for surgery in patients with ulcerative colitis in the presence of concomitant immune-mediated diseases (HR 1.56, 95% CI 1.04-2.35) ( Figure S2) .
We repeated our analysis in broad groupings of type of immune-mediated disease by organ system affected, recognising that there are many ways to classify immune-mediated diseases. For anti-TNF use, the strongest association with increased frequency of use was observed with concurrent musculoskeletal (rheumatoid arthritis, ankylosing spondylitis) (62% vs. 47%, P = 0.025) and cutaneous immune-mediated diseases (psoriasis, vitiligo, alopecia areata) (58% vs. 46%, P = 0.006) with a trend towards increased use with respiratory immune-mediated diseases (asthma, Wegener's granulomatosis) (52% vs. 46%, P = 0.10). For the outcome of ever needing bowel resection surgery, a significant increase in risk was noted with cutaneous immune-mediated diseases (44% vs. 31%, P = 0.001) with a trend towards increased risk with respiratory (P = 0.10) and musculoskeletal (P = 0.11) immunemediated diseases.
Quality of life associations between patients with immune-mediated diseases and IBD A total of 1828 patients completed the surveys related to quality of life, 417 patients with autoimmune disease and IBD and 1411 patients with IBD alone. Figure 2 The prevalence of another immune-mediated disease in our cohort was 21%. This is comparable to the prevalence identified in other cohorts and supports an increase in the frequency of these diseases in those with IBD as has been demonstrated by several previous studies. 13-15, 17-21, 31 The most common immune-mediated diseases in our cohort were asthma and psoriasis, both of which have been commonly reported in other cohorts as well and to occur at an increased frequency in those with IBD. A population-based study from the University of Manitoba in Canada demonstrated an increased risk of several immune-mediated diseases in patients with IBD. 14 Among them, asthma was the most common comorbidity affecting 21% of UC patients and 20% of those with CD compared to 15% of controls. As well 9% of IBD patients had psoriasis, the second most common immune-mediated disease, compared to 6% of controls. These estimates from cross-sectional studies have been confirmed in prospective cohorts. A large study from Taiwan comprising 5260 patients with IBD demonstrated 1.5-fold increase in risk of asthma. 32 An analysis of the Nurses Health study showed a fourfold increase in risk of CD (but not UC) in those with psoriasis, suggesting bi-directional association. 33 However, despite shared genetics, not all immune-mediated diseases are more common in those with IBD. For example, prevalence of coeliac disease in IBD is similar to the general population. 34, 35 Few of these large studies examined if co-occurrence of immune-mediated diseases predict a more severe course of IBD. Our findings suggest more frequent pancolitis phenotype of UC in those with another immunemediated disease, greater disease activity and an increase in need for anti-TNF and intestinal resection surgery. While the use of biologics may represent a shared therapeutic mechanism for both IBD and the immunemediated disease, this is unlikely to be the main determinant as it would not explain the need for surgery in this population. Few studies have previously examined the impact of co-occurring immune-mediated diseases on the natural history and phenotype of IBD. Most of the literature has focused on the impact of primary sclerosing cholangitis (PSC) on IBD. 21-24, 36, 37 IBD that occurs in the setting of PSC favours ulcerative pancolitis and infrequently demonstrates isolated ileal involvement in CD. 37, 38 In contrast with our findings of no effect of PSC on natural history of IBD, other studies have suggested that the behaviour of underlying IBD tends to be milder, particularly in patients with severe PSC. In a cross-sectional study, the severity of IBD was greater when PSC occurred in conjunction with UC than CD, with a higher risk for colectomy and colon neoplasia in this population. 39 The need for colectomy is frequently lower in patients who required liver transplantation for their PSC. [22] [23] [24] Less data exist examining the impact of other immune-mediated diseases on IBD. A single case report described a severe course of ulcerative colitis in a patient with rheumatoid arthritis. 40 In a study of 51
IBD patients with co-existing coeliac disease, a trend towards more frequent pancolonic involvement and requirement for immunomodulators was noted in those with UC with no impact on those with CD. 19 A small case series of fewer than 10 patients each with coeliac disease and IBD demonstrated high rates of surgical intervention but was limited by being referral centre in origin and lacking a control group. 41 A small study of 67 children with UC did not demonstrate a difference in clinical course between those with and without concomitant autoimmune diseases though the small sample size limited statistical power and a majority of the patients had PSC as the underlying autoimmune disease. 18 Importantly, our findings suggested that patient with concomitant immune-mediated diseases experience significantly greater impairment in disease-specific and general physical quality of life in comparison to those without such diseases. Several factors are known to influence HRQoL in patients with IBD, importantly female gender, disease activity and comorbidity. [42] [43] [44] While the impairment of quality of life in individuals with chronic immune-mediated diseases is well recognised few studies have examined whether co-occurrence further impairs HRQoL. [45] [46] [47] [48] [49] [50] A single centre study of patients with PSC and IBD did not find any impairment of HRQoL. 36 However, general quality of life scores were not ascertained and PSC-IBD is usually milder. Our findings are similar to that Pizzi et al. who demonstrated that chronic co-morbidities including other autoimmune diseases exerted a significant negative impact on both physical and mental HRQoL in patients with IBD though a stronger effect was seen for comorbid depression and anxiety. 48 This study examining the impact of the co-occurrence of IBD and immune-mediated diseases has a few implications. There are three potential mechanisms how cooccurrence of other immune-mediated diseases may influence phenotype and natural history of IBD. First, a wealth of literature highlights that some genes and genetic pathways are shared between different immunemediated diseases. For example, the interleukin-12/23 pathway is pertinent to the development of both CD and psoriasis supported by the shared efficacy of monoclonal antibody targeting this pathway (ustekinumab) in both diseases. Thus, specific phenotypes that are enriched in this population with co-occurrence may be mediated by such shared genetic pathways. Second, environmental factors that are common to both diseases may contribute to the more severe natural history. For example, smoking is a known risk factor for asthma and IBD, and in turn, may lead to more severe disease course in patients who have both IBD and asthma. Some environmental factors such as nonsteroidal anti-inflammatory drugs (NSAIDs) may be as a consequence of one immune-mediated disease (such as rheumatoid arthritis) and trigger relapses of IBD. Finally, studies have also suggested that many immune-mediated diseases may share common gut microbial triggers. 2 Animal models in various immunemediated diseases including IBD, rheumatoid arthritis, lupus, multiple sclerosis and ankylosing spondylitis all demonstrate a role for the microbiome in disease pathogenesis. While each disease appears to have distinct microbial signatures, there are some changes that may be common across diseases, for example, reduction in faecalibacterium and increase in Escherichia in patients with Crohn's disease and multiple sclerosis. 2 While the impact of gut microbial composition on disease phenotype is not well defined, such sharing of microbial triggers may also contribute to more severe disease in those with cooccurrence IBD and other immune-mediate diseases. In addition, our findings highlight the deleterious impact of concomitant comorbid conditions on quality of life and the need to ascertain factors that impact such QoL and may be modified to improve patient outcomes. There are several limitations to this study. First, since the study was conducted at a tertiary referral centre, the disease severity in our study may be greater than in population-based cohorts. Assessment of disease activity was cross-sectional at a single time point. Although the size of our cohort was larger than many previous publications, the number of patients with each immunemediated disease was small precluding an examination of the effect of each individual disease. Finally, certain immune-mediated diseases may have treatment options that overlap with IBD, for example psoriasis and rheumatoid arthritis. Thus, it may not always be possible to discern which the primary determinant of escalating immunosuppression is. However, we did not exclude such patients from our primary analysis to avoid compromising the generalisability of the cohort. A trend towards increase rates of anti-TNF use and surgery remained on exclusion of such patients. Furthermore, recent analysis of Medicare data revealed that fewer than 5% each of patients with psoriasis were on infliximab or adalimumab therapy suggesting that in the majority of patients, psoriasis is unlikely to be the main factor determining need for anti-TNF use. 51 Disease activity indices and inflammatory markers were available at a single time point; cumulative burden of such measures over time may provide additional data regarding the longitudinal impact of concomitant immune-mediated diseases on natural history of IBD. We also did not have information on the sequence of diagnosis of IBD and other immune-mediated diseases and whether onset before or after the diagnosis of IBD differentially impacted natural history.
In conclusion, co-occurrence of another immunemediated disease in patients with IBD was associated with greater disease activity and a modest increase in need for anti-TNF medications and surgery, suggesting a potential impact on disease severity. The mechanism and impact of the clustering of immune-mediated diseases merits greater study to better understand the aetiology of these diseases and develop therapeutic algorithms to improve patient outcomes.
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